4 items found in 1 pages
TRACERx: How whole-genome doubling helps cancer survive
Dr Nicholas McGranahan, joint lead for the TRACERx team at UCL, explains the survival advantage to cancer of doubling its genome: If one copy of the genome has a lethal mutation, the cell could continue to survive and divide, thanks to its second copy - a genetic 'spare tyre.' Read more on the CRUK blog: https://scienceblog.cancerresearchuk.org/2020/03/05/evolution-sex-and-tracerx-how-cancers-spare-tyre-helps-it-survive/ Research paper: Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics
365
5/21/2020
Rethinking Cancer Panel Discussion - Cancer evolution: can we beat Nature?
Professor Alison Lloyd Professor Andrew Pomiankowski Professor Charles Swanton Dr Duncan Greig Professor David Gems Professor Tariq Enver Rethinking Cancer | UCL Cancer Domain Symposium Monday 13 May 2019 Cancer evolution: can we beat Nature? Cancer remains one of the major causes of morbidity and premature death worldwide; one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime. UCL has a proud track record in addressing the societal, technical, and health challenges of cancer and in exploring its underling biology. This symposium, invited our broad community to assemble for the first time at scale to consider challenges and opportunities in cancer research, prevention and treatment, from biological, clinical, technical, economic and societal perspectives.
698
6/3/2019
Professor Charles Swanton - Cancer evolution, immune evasion and metastatic progression - insights from TRACERx
Prof Charles Swanton UCL Cancer Institute & The Francis Crick Institute Director, CRUK UCL Lung Cancer Centre Rethinking Cancer | UCL Cancer Domain Symposium Monday 13 May 2019 Cancer evolution: can we beat Nature? Cancer remains one of the major causes of morbidity and premature death worldwide; one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime. UCL has a proud track record in addressing the societal, technical, and health challenges of cancer and in exploring its underling biology. This symposium, invited our broad community to assemble for the first time at scale to consider challenges and opportunities in cancer research, prevention and treatment, from biological, clinical, technical, economic and societal perspectives.
682
6/3/2019
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
The immune system is constantly on the lookout for diseased cells. Every cell in our body has signals on their surface that reach out to immune cells, letting them know if everything is ok, or if the cell is unhealthy. Signals from diseased cells will cause the immune system to attack and kill those faulty cells. But in many lung cancers, the cancer cells lose about half of those signals to the immune system. This lets the cancer cells hide from the immune attacks, and allows the cancer to keep growing. Researchers have developed a computational toolset to help investigate how many of these signals to the immune cells are left on a cancer cell, based on DNA sequencing information. Hopefully this will help us develop more focused immune therapy in the future. First author: Rachel Rosenthal Corresponding authors: Professor Charles Swanton and Dr Nicholas McGranahan Research paper: http://www.cell.com/cell/fulltext/S0092-8674(17)31185-6
12578
11/3/2017